Compare Global E Online Ltd (GLBE) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Johnson & Johnson — how do they compare? Global E Online Ltd trades at $40.17 (market cap $6.75B), while Johnson & Johnson trades at $260.52 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 91.6× Global E Online Ltd's market cap, and Johnson & Johnson pays a 2.09% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Johnson & Johnson for 129 Days on average.
| GLBE | JNJ | |
|---|---|---|
Market Cap | $6.75B | $618.09B |
Volume | 1,468,708 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $278.43 |
52-Week Low | $27.54 | $186.00 |
Typical Hold Time | 21 Days | 129 Days |
Enterprise Value | $6.24B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.25, up 3.31% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth of 39% year-over-year. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, supported by strong revenue growth, expanding margins, and a high analyst buy rating. Key risks include elevated valuation multiples, insider selling pressure, and dependence on e-commerce market conditions. The stock offers potential upside to the consensus price target of $48.86.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
